Alzheimer’s drug fail in clinical trials

Clinical trials for solanezumab, a drug that it was hoped would slow down the onset of Alzheimer’s disease, have failed at the final phase three stage. Eli Lilly, the pharmaceutical company behind the latest trials, announced recently that results showed there are no benefits to a patient’s memory from taking the drug. Image Credit Hopes […]